Abstract:Glioblastoma (GBM) is an aggressive malignancy of the central nervous system (CNS) that remains incurable despite the multitude of improvements in cancer therapeutics. The conventional chemo and radiotherapy post-surgery have only been able to improve the prognosis slightly; however, the development of resistance and/or tumor recurrence is almost inevitable. There is a pressing need for adjuvant molecular therapies that can successfully and efficiently block tumor progression. During the last few decades, non-coding RNAs (ncRNAs) have emerged as key players in regulating various hallmarks of cancer including that of GBM. The levels of many ncRNAs are dysregulated in cancer, and ectopic modulation of their levels by delivering antagonists or overexpression constructs could serve as an attractive option for cancer therapy. The therapeutic potential of several types of ncRNAs, including miRNAs, lncRNAs, and circRNAs, has been validated in both in vitro and in vivo models of GBM. However, the delivery of these RNA-based therapeutics is highly challenging, especially to the tumors of the brain as the blood-brain barrier (BBB) poses as a major obstacle, among others. Also, since RNA is extremely fragile in nature, careful considerations must be met while designing a delivery agent. In this review we have shed light on how ncRNA therapy can overcome the limitations of its predecessor conventional therapy with an emphasis on smart nanomaterials that can aide in the safe and targeted delivery of nucleic acids to treat GBM. Additionally, critical gaps that currently exist for successful transition from viral to non-viral vector delivery systems have been identified. Finally, we have provided a perspective on the future directions, potential pathways, and target areas for achieving rapid clinical translation of, RNA-based macromolecular therapy to advance the effective treatment of GBM and other related diseases.

Ribozyme-Spherical Nucleic Acids.

In vitro cleavage of mdrl mrna fragment by synthetic ribozyme (rz) and transcribed ribozyme from tna-trimming plasmid

Synthesis, Physicochemical, and Biological Evaluation of Spherical Nucleic Acids for RNAi-Based Therapy in Glioblastoma

Dual Bioluminescence and Near-Infrared Fluorescence Monitoring to Evaluate Spherical Nucleic Acid Nanoconjugate Activity in Vivo

Spherical Nucleic Acid Nanoparticle Conjugates As an RNAi-Based Therapy for Glioblastoma*

Ribozyme and Its Design As Molecular Drug and Application

Cleaving Folded RNA by Multifunctional DNAzyme Nanomachines

RNA-based programmable DNA cleavage

Marker‐dependent cleavage of RNA by binary (split) DNAzyme (BiDz) and binary DNA machines (biDNM)

The Effector Mechanism of Sirna Spherical Nucleic Acids.

Targeting Ribonucleases with Small Molecules and Bifunctional Molecules

Brain-Targeted polymersome codelivery of siRNA and temozolomide for

Ribozyme-Mediated Cleavage of the Estrogen Receptor Messenger Rna and Inhibition of Receptor Function in Target Cells

A Novel Small RNA-Cleaving Deoxyribozyme with a Short Binding Arm

Engineered smart materials for RNA based molecular therapy to treat Glioblastoma

How Natural Enzymes and Synthetic Ribozymes Generate Methylated Nucleotides in RNA

Targeted Inhibition of Oncogenic Mir-21 Maturation with Designed RNA-binding Proteins.

Cell‐Specific Control of Mammalian Gene Expression Using DNA Repair Inducible Ribozyme Switches

Reversal MDR in Breast Carcinoma Cells by Transfection of Ribozyme Designed According the Secondary Structure of Mdr1 Mrna.

Boosting RNAi Therapy for Orthotopic Glioblastoma with Nontoxic Brain-Targeting Chimaeric Polymersomes

G-Quadruplex mRNAs Silencing with Inducible Ribonuclease Targeting Chimera for Precision Tumor Therapy